Milena Sant, Claudia Vener, Roberto Lillini, Silvia Rossi, Simone Bonfarnuzzo, Rafael Marcos-Gragera, Marc Maynadié, Kaire Innos, Keiu Paapsi, Otto Visser, Alice Bernasconi, Elena Demuru, Corrado Di Benedetto, Seyed Mohsen Mousavi, Marcel Blum, Philip Went, Diego Serraino, Damien Bennett, Maria-Jose Sánchez, Roberta De Angelis
BACKGROUND: Management of lymphoid malignancies requires substantial health system resources. Total national health expenditure might influence population-based lymphoid malignancy survival. We studied the long-term survival of patients with 12 lymphoid malignancy types and examined whether different levels of national health expenditure might explain differences in lymphoid malignancy prognosis between European countries and regions. METHODS: For this observational, retrospective, population-based study, we analysed the EUROCARE-6 dataset of patients aged 15 or older diagnosed between 2001 and 2013 with one of 12 lymphoid malignancies defined according to International Classification of Disease for Oncology (third edition) and WHO classification, and followed up to 2014 (Jan 1, 2001-Dec 31, 2014)...
May 1, 2024: Lancet Oncology